Rafael (NYSE:RFL) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Rafael (NYSE:RFL) to a hold rating in a research note released on Saturday morning.

Separately, Weiss Ratings raised shares of Rafael from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, May 28th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Rafael Stock Performance

Shares of RFL stock opened at $2.26 on Friday. Rafael has a 52-week low of $1.12 and a 52-week high of $3.96. The stock has a market cap of $117.31 million, a price-to-earnings ratio of -3.32 and a beta of 0.29. The firm has a fifty day moving average of $2.18 and a 200-day moving average of $1.59.

Institutional Trading of Rafael

Large investors have recently bought and sold shares of the stock. Geode Capital Management LLC raised its stake in Rafael by 72.9% during the second quarter. Geode Capital Management LLC now owns 451,139 shares of the company’s stock worth $781,000 after acquiring an additional 190,179 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of Rafael in the 2nd quarter valued at $50,000. Cable Car Capital LP acquired a new stake in shares of Rafael in the 2nd quarter valued at $173,000. Vanguard Group Inc. boosted its stake in shares of Rafael by 10.5% in the 3rd quarter. Vanguard Group Inc. now owns 1,394,726 shares of the company’s stock valued at $1,897,000 after purchasing an additional 133,024 shares in the last quarter. Finally, Citadel Advisors LLC grew its holdings in shares of Rafael by 132.3% in the 3rd quarter. Citadel Advisors LLC now owns 72,584 shares of the company’s stock worth $99,000 after purchasing an additional 41,335 shares during the last quarter. 11.30% of the stock is currently owned by institutional investors.

Rafael Company Profile

Rafael Holdings, Inc primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia.